PD-L1 Inhibitors for the Treatment of Prostate Cancer

doi:10.2174/1389450121666200609142219
摘要

前列腺癌（PCa）的致癌作用来自一系列复杂的事件。在这种情况下，慢性炎症和感染至关重要。浸润的M2型巨噬细胞以及嗜中性粒细胞和T淋巴细胞有助于PCa的发育，发展和对治疗的反应。关于PCa患者免疫治疗功效的初步发现并不令人鼓舞。但是，在该肿瘤中，正在进行一系列研究，涉及单独使用或与其他免疫疗法，化学疗法或局部区域疗法联合使用的抗PD-L1药物，如Atezolizumab，Avelumab和Durvalumab。在这篇综述中，我们说明了免疫细胞和PD-L1表达在PCa癌变和进展过程中的作用，重点是在这种情况下正在进行的有关抗PD-L1药物的临床试验。
关键词: Atezolizumab，avelumab，durvalumab，免疫疗法，PD-L1，前列腺癌。
« Previous Next »
图形摘要

[1] 
Drake CG, Lipson EJ, Brahmer JR. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol  2014; 11(1): 24-37.
[http://dx.doi.org/10.1038/nrclinonc.2013.208] [PMID: 24247168] 
[2] 
Martin-Liberal J, Ochoa de Olza M, Hierro C, Gros A, Rodon J, Tabernero J. The expanding role of immunotherapy. Cancer Treat Rev  2017; 54: 74-86.
[http://dx.doi.org/10.1016/j.ctrv.2017.01.008] [PMID: 28231560] 
[3] 
Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med  2012; 366(26): 2443-54.
[http://dx.doi.org/10.1056/NEJMoa1200690] [PMID: 22658127] 
[4] 
Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med  2012; 366(26): 2455-65.
[http://dx.doi.org/10.1056/NEJMoa1200694] [PMID: 22658128] 
[5] 
Lindberg J, Kristiansen A, Wiklund P, Grönberg H, Egevad L. Tracking the origin of metastatic prostate cancer. Eur Urol  2015; 67(5): 819-22.
[http://dx.doi.org/10.1016/j.eururo.2014.09.006] [PMID: 25246081] 
[6] 
Piva F, Santoni M, Scarpelli M, Briganti A, Montorsi F, Montironi R. Re: Johan Lindberg, Anna Kristiansen, Peter Wiklund, Henrik Grönberg, Lars Egevad. Tracking the origin of metastatic prostate Cancer. Eur Urol  2015; 68(6): e134-5.
[http://dx.doi.org/10.1016/j.eururo.2015.07.011] [PMID: 26215609] 
[7] 
Santoni M, Piva F, Scarpelli M, et al. The origin of prostate metastases: emerging insights. Cancer Metastasis Rev  2015; 34(4): 765-73.
[http://dx.doi.org/10.1007/s10555-015-9597-6] [PMID: 26363603] 
[8] 
Baca SC, Prandi D, Lawrence MS, et al. Punctuated evolution of prostate cancer genomes. Cell  2013; 153(3): 666-77.
[http://dx.doi.org/10.1016/j.cell.2013.03.021] [PMID: 23622249] 
[9] 
Gundem G, Van Loo P, Kremeyer B, et al. ICGC Prostate Group The evolutionary history of lethal metastatic prostate cancer. Nature  2015; 520(7547): 353-7.
[http://dx.doi.org/10.1038/nature14347] [PMID: 25830880] 
[10] 
Ciccarese C, Santoni M, Massari F, et al. Metabolic alterations in renal and prostate cancer. Curr Drug Metab  2016; 17(2): 150-5.
[http://dx.doi.org/10.2174/1389200216666151015112356] [PMID: 26467063] 
[11] 
Swinnen JV, Vanderhoydonc F, Elgamal AA, et al. Selective activation of the fatty acid synthesis pathway in human prostate cancer. Int J Cancer  2000; 88(2): 176-9.
[http://dx.doi.org/10.1002/1097-0215(20001015)88:2<176:AID-IJC5>3.0.CO;2-3] [PMID: 11004665] 
[12] 
Santoni M, Conti A, Burattini L, et al. Neuroendocrine differentiation in prostate cancer: novel morphological insights and future therapeutic perspectives. Biochim Biophys Acta  2014; 1846(2): 630-7.
[PMID: 25450825] 
[13] 
Vitkin N, Nersesian S, Siemens DR, Koti M. The Tumor Immune Contexture of Prostate Cancer. Front Immunol  2019; 10: 603.
[http://dx.doi.org/10.3389/fimmu.2019.00603] [PMID: 30984182] 
[14] 
Sfanos KS, Hempel HA, De Marzo AM. The role of inflammation in prostate cancer. Adv Exp Med Biol  2014; 816: 153-81.
[http://dx.doi.org/10.1007/978-3-0348-0837-8_7] [PMID: 24818723] 
[15] 
Gucalp A, Iyengar NM, Zhou XK, et al. Periprostatic adipose inflammation is associated with high-grade prostate cancer. Prostate Cancer Prostatic Dis  2017; 20(4): 418-23.
[http://dx.doi.org/10.1038/pcan.2017.31] [PMID: 28653675] 
[16] 
Wang W, Bergh A, Damber JE. Morphological transition of proliferative inflammatory atrophy to high-grade intraepithelial neoplasia and cancer in human prostate. Prostate  2009; 69(13): 1378-86.
[http://dx.doi.org/10.1002/pros.20992] [PMID: 19507201] 
[17] 
Xie DD, Chen YH, Xu S, et al. Low vitamin D status is associated with inflammation in patients with prostate cancer. Oncotarget  2017; 8(13): 22076-85.
[http://dx.doi.org/10.18632/oncotarget.16195] [PMID: 28423553] 
[18] 
Mrakovčić-Šutić I, Sotošek Tokmadžić V, Ilić Tomaš M, et al. Cross talk between nkt and regulatory t cells (tregs) in prostatic tissue of patients with benign prostatic hyperplasia and prostate cancer. Period Biol  2014; 116: 409-15.
[19] 
De Nunzio C, Presicce F, Tubaro A. Inflammatory mediators in the development and progression of benign prostatic hyperplasia. Nat Rev Urol  2016; 13(10): 613-26.
[http://dx.doi.org/10.1038/nrurol.2016.168] [PMID: 27686153] 
[20] 
Santoni M, Cheng L, Conti A, et al. Activity and functions of tumor-associated macrophages in prostate carcinogenesis. Eur Urol Suppl  2019; 16: 301-8.
[http://dx.doi.org/10.1016/j.eursup.2017.09.002] 
[21] 
Cha HR, Lee JH, Hensel JA, et al. Prostate cancer-derived cathelicidin-related antimicrobial peptide facilitates macrophage differentiation and polarization of immature myeloid progenitors to protumorigenic macrophages. Prostate  2016; 76(7): 624-36.
[http://dx.doi.org/10.1002/pros.23155] [PMID: 26856684] 
[22] 
Hagemann T, Wilson J, Kulbe H, et al. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol  2005; 175(2): 1197-205.
[http://dx.doi.org/10.4049/jimmunol.175.2.1197] [PMID: 16002723] 
[23] 
Li N, Grivennikov SI, Karin M. The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment. Cancer Cell  2011; 19(4): 429-31.
[http://dx.doi.org/10.1016/j.ccr.2011.03.018] [PMID: 21481782] 
[24] 
Fang LY, Izumi K, Lai KP, et al. Infiltrating macrophages promote prostate tumorigenesis via modulating androgen receptor-mediated CCL4-STAT3 signaling. Cancer Res  2013; 73(18): 5633-46.
[http://dx.doi.org/10.1158/0008-5472.CAN-12-3228] [PMID: 23878190] 
[25] 
Maolake A, Izumi K, Shigehara K, et al. Tumor-associated macrophages promote prostate cancer migration through activation of the CCL22-CCR4 axis. Oncotarget  2017; 8(6): 9739-51.
[http://dx.doi.org/10.18632/oncotarget.14185] [PMID: 28039457] 
[26] 
Lee GT, Kwon SJ, Lee JH, et al. Macrophages induce neuroendocrine differentiation of prostate cancer cells via BMP6-IL6 Loop. Prostate  2011; 71(14): 1525-37.
[http://dx.doi.org/10.1002/pros.21369] [PMID: 21374653] 
[27] 
Halin S, Rudolfsson SH, Van Rooijen N, Bergh A. Extratumoral macrophages promote tumor and vascular growth in an orthotopic rat prostate tumor model. Neoplasia  2009; 11(2): 177-86.
[http://dx.doi.org/10.1593/neo.81338] [PMID: 19177202] 
[28] 
Roca H, Varsos ZS, Sud S, Craig MJ, Ying C, Pienta KJ. CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem  2009; 284(49): 34342-54.
[http://dx.doi.org/10.1074/jbc.M109.042671] [PMID: 19833726] 
[29] 
Ok Atılgan A, Özdemir BH, Akçay EY, Ataol Demirkan Ö, Tekindal MA, Özkardeş H. Role of tumor-associated macrophages in the Hexim1 and TGFβ/SMAD pathway, and their influence on progression of prostatic adenocarcinoma. Pathol Res Pract  2016; 212(2): 83-92.
[http://dx.doi.org/10.1016/j.prp.2015.10.011] [PMID: 26608417] 
[30] 
Strasner A, Karin M. Immune infiltration and prostate cancer. Front Oncol  2015; 5: 128.
[http://dx.doi.org/10.3389/fonc.2015.00128] [PMID: 26217583] 
[31] 
Zhang Y, Zhang Z, Zhang L, et al. Clinical Implications of Peripheral CD3+CD69+ T-cell and CD8+CD28+ T-cell Proportions in Patients Prior to Radical Prostatectomy. Urol J in press  2020; 17(3): 257-61.
[http://dx.doi.org/10.22037/uj.v0i0.5103] [PMID: 31630384] 
[32] 
Kwek SS, Lewis J, Zhang L, et al. Preexisting levels of cd4 t cells expressing pd-1 are related to overall survival in prostate cancer patients treated with ipilimumab. Cancer Immunol Res  2015; 3(9): 1008-16.
[http://dx.doi.org/10.1158/2326-6066.CIR-14-0227] [PMID: 25968455] 
[33] 
Evans JD, Morris LK, Zhang H, et al. Prospective immunophenotyping of cd8+ t cells and associated clinical outcomes of patients with oligometastatic prostate cancer treated with metastasis-directed sbrt. Int J Radiat Oncol Biol Phys  2019; 103(1): 229-40.
[http://dx.doi.org/10.1016/j.ijrobp.2018.09.001] [PMID: 30205124] 
[34] 
Bahig H, Taussky D, Delouya G, et al. Neutrophil count is associated with survival in localized prostate cancer. BMC Cancer  2015; 15: 594.
[http://dx.doi.org/10.1186/s12885-015-1599-9] [PMID: 26292807] 
[35] 
Vidal AC, Howard LE, de Hoedt A, et al. Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database. Cancer Causes Control  2018; 29(6): 581-8.
[http://dx.doi.org/10.1007/s10552-018-1031-2] [PMID: 29663110] 
[36] 
Minardi D, Scartozzi M, Montesi L, et al. Neutrophil-to-lymphocyte ratio may be associated with the outcome in patients with prostate cancer. Springerplus  2015; 4: 255.
[http://dx.doi.org/10.1186/s40064-015-1036-1] [PMID: 26085975] 
[37] 
Buttigliero C, Tucci M, Vignani F, et al. Chemotherapy-induced neutropenia and outcome in patients with metastatic castration-resistant prostate cancer treated with first-line docetaxel. Clin Genitourin Cancer  2018; 16(4): 318-24.
[http://dx.doi.org/10.1016/j.clgc.2018.05.006] [PMID: 29866495] 
[38] 
Scimeca M, Bonfiglio R, Urbano N, et al. Programmed death ligand 1 expression in prostate cancer cells is associated with deep changes of the tumor inflammatory infiltrate composition Urol Oncol  2019; 37(5): 297. e19-.
[http://dx.doi.org/10.1016/j.urolonc.2019.02.013] [PMID: 30827759] 
[39] 
Lindh C, Kis L, Delahunt B, et al. PD-L1 expression and deficient mismatch repair in ductal adenocarcinoma of the prostate. APMIS  2019; 127(8): 554-60.
[http://dx.doi.org/10.1111/apm.12970] [PMID: 31127651] 
[40] 
Fankhauser CD, Schüffler PJ, Gillessen S, et al. Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer. Oncotarget  2017; 9(12): 10284-93.
[PMID: 29535806] 
[41] 
Nava Rodrigues D, Rescigno P, Liu D, et al. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. J Clin Invest  2018; 128(10): 4441-53.
[http://dx.doi.org/10.1172/JCI121924] [PMID: 30179225] 
[42] 
Wu YM, Cieślik M, Lonigro RJ, et al. PCF/SU2C international prostate cancer dream team. inactivation of cdk12 delineates a distinct immunogenic class of advanced prostate cancer. Cell  2018; 173(7): 1770-82.e14.
[http://dx.doi.org/10.1016/j.cell.2018.04.034] [PMID: 29906450] 
[43] 
Vidotto T, Saggioro FP, Jamaspishvili T, et al. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells. Prostate  2019; 79(9): 969-79.
[http://dx.doi.org/10.1002/pros.23808] [PMID: 30999388] 
[44] 
Mo RJ, Han ZD, Liang YK, et al. Expression of PD-L1 in tumor-associated nerves correlates with reduced CD8+ tumor-associated lymphocytes and poor prognosis in prostate cancer. Int J Cancer  2019; 144(12): 3099-110.
[http://dx.doi.org/10.1002/ijc.32061] [PMID: 30537104] 
[45] 
Petitprez F, Fossati N, Vano Y, et al. PD-L1 Expression and CD8+ t-cell infiltrate are associated with clinical progression in patients with node-positive prostate cancer. Eur Urol Focus  2019; 5(2): 192-6.
[http://dx.doi.org/10.1016/j.euf.2017.05.013] [PMID: 28753812] 
[46] 
Rekoske BT, Olson BM, McNeel DG. Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses. OncoImmunology  2016; 5(6)e1165377
[http://dx.doi.org/10.1080/2162402X.2016.1165377] [PMID: 27471641] 
[47] 
Graff JN, Alumkal JJ, Drake CG, et al. Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget  2016; 7(33): 52810-7.
[http://dx.doi.org/10.18632/oncotarget.10547] [PMID: 27429197] 
[48] 
Raman R, Vaena D. Immunotherapy in metastatic renal cell carcinoma: a comprehensive review. BioMed Res Int 2015.2015367354
[http://dx.doi.org/10.1155/2015/367354] [PMID: 26161397] 
[49] 
Rittmeyer A, Barlesi F, Waterkamp D, et al. OAK Study Group Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet  2017; 389(10066): 255-65.
[http://dx.doi.org/10.1016/S0140-6736(16)32517-X] [PMID: 27979383] 
[50] 
Horn L, Mansfield AS, Szczęsna A, et al. IMpower133 study group. first-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med  2018; 379(23): 2220-9.
[http://dx.doi.org/10.1056/NEJMoa1809064] [PMID: 30280641] 
[51] 
Socinski MA, Jotte RM, Cappuzzo F, et al. IMpower150 study group. atezolizumab for first-line treatment of metastatic nonsquamous nsclc. N Engl J Med  2018; 378(24): 2288-301.
[http://dx.doi.org/10.1056/NEJMoa1716948] [PMID: 29863955] 
[52] 
Powles T, Durán I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet  2018; 391(10122): 748-57.
[http://dx.doi.org/10.1016/S0140-6736(17)33297-X] [PMID: 29268948] 
[53] 
Schmid P, Adams S, Rugo HS, et al. IMpassion130 Trial Investigators. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med  2018; 379(22): 2108-21.
[http://dx.doi.org/10.1056/NEJMoa1809615] [PMID: 30345906] 
[54] 
Rini BI, Powles T, Atkins MB, et al. IMmotion151 Study Group. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet  2019; 393(10189): 2404-15.
[http://dx.doi.org/10.1016/S0140-6736(19)30723-8] [PMID: 31079938] 
[55] 
Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol  2016; 17(10): 1374-85.
[http://dx.doi.org/10.1016/S1470-2045(16)30364-3] [PMID: 27592805] 
[56] 
Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med  2019; 380(12): 1103-15.
[http://dx.doi.org/10.1056/NEJMoa1816047] [PMID: 30779531] 
[57] 
Antonia SJ, Villegas A, Daniel D, et al. PACIFIC investigators durvalumab after chemoradiotherapy in stage iii non-small-cell lung cancer. N Engl J Med  2017; 377(20): 1919-29.
[http://dx.doi.org/10.1056/NEJMoa1709937] [PMID: 28885881] 
[58] 
Rijnders M, de Wit R, Boormans JL, Lolkema MPJ, van der Veldt AAM. Systematic review of immune checkpoint inhibition in urological cancers. Eur Urol  2017; 72(3): 411-23.
[http://dx.doi.org/10.1016/j.eururo.2017.06.012] [PMID: 28645491] 
[59] 
Dudek AZ, Liu LC, Alva AS, Stein M, Gupta S, Albany C, et al. Phase ib and phase II studies of pembrolizumab (P) with bevacizumab (B) for the treatment of metastatic renal cell carcinoma (RCC): BTCRC-GU14-003. J Clin Oncol  2018; 3615: 4558-8.
[60] 
Chowdhury S, McDermott DF, Voss MH, et al. A phase I/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC). J Clin Oncol  2017; 1515: 4506-6.
[61] 
Hammers HJ, Plimack ER, Infante JR, et al. Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. J Clin Oncol  2017; 35(34): 3851-8.
[http://dx.doi.org/10.1200/JCO.2016.72.1985] [PMID: 28678668] 
[62] 
Santoni M, Scarpelli M, Mazzucchelli R, et al. Current histopathologic and molecular characterisations of prostate cancer: towards individualised prognosis and therapies. Eur Urol  2016; 69(2): 186-90.
[http://dx.doi.org/10.1016/j.eururo.2015.05.041] [PMID: 26070514] 
[63] 
Cimadamore A, Santoni M, Massari F, et al. Microbiome and Cancers, With Focus on Genitourinary Tumors. Front Oncol  2019; 9: 178.
[http://dx.doi.org/10.3389/fonc.2019.00178] [PMID: 30972292] 
[64] 
Bersanelli M, Santoni M, Ticinesi A, Buti S. The urinary microbiome and anticancer immunotherapy: the potentially hidden role of unculturable microbes. Target Oncol  2019; 14(3): 247-52.
[http://dx.doi.org/10.1007/s11523-019-00643-7] [PMID: 31073691] 
[65] 
Shrestha E, White JR, Yu SH, et al. Profiling the Urinary Microbiome in Men with Positive versus Negative Biopsies for Prostate Cancer. J Urol  2018; 199(1): 161-71.
[http://dx.doi.org/10.1016/j.juro.2017.08.001] [PMID: 28797714] 
[66] 
Massari F, Mollica V, Di Nunno V, et al. The human microbiota and prostate cancer: friend or foe? Cancers (Basel)  2019; 11(4)E459
[http://dx.doi.org/10.3390/cancers11040459] [PMID: 30935126] 
[67] 
Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science  2018; 359(6371): 91-7.
[http://dx.doi.org/10.1126/science.aan3706] [PMID: 29097494] 
[68] 
Santoni M, Piva F, Conti A, et al. Re: Gut microbiome influences efficacy of pd-1-based immunotherapy against epithelial tumors. Eur Urol  2018; 74(4): 521-2.
[http://dx.doi.org/10.1016/j.eururo.2018.05.033] [PMID: 29891391] 
[69] 
Strauss J, Heery CR, Schlom J, et al. Phase i trial of m7824 (msb0011359c), a bifunctional fusion protein targeting pd-l1 and tgfβ, in advanced solid tumors. Clin Cancer Res  2018; 24(6): 1287-95.
[http://dx.doi.org/10.1158/1078-0432.CCR-17-2653] [PMID: 29298798] 
Rights & Permissions Print Cite
Article Metrics
41
2
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/1389450121666200609142219	Print ISSN 1389-4501
Publisher Name Bentham Science Publisher	Online ISSN 1873-5592
当代药物靶点

PD-L1抑制剂治疗前列腺癌

摘要

图形摘要

当代药物靶点

PD-L1抑制剂治疗前列腺癌

摘要 Play Pause

图形摘要

Related Journals

Related Books

Related Articles

摘要
